HL Acquisitions (NASDAQ:IMTX) Trading Up 7.2%

HL Acquisitions Corp. (NASDAQ:IMTX)’s stock price was up 7.2% during trading on Thursday . The stock traded as high as $11.73 and last traded at $11.37. Approximately 592,724 shares changed hands during trading, an increase of 194% from the average daily volume of 201,346 shares. The stock had previously closed at $10.61.

Several equities research analysts recently commented on IMTX shares. Goldman Sachs Group started coverage on shares of HL Acquisitions in a research note on Monday, September 21st. They set a “buy” rating and a $17.00 price target on the stock. Chardan Capital restated a “buy” rating and issued a $28.00 price objective on shares of HL Acquisitions in a research note on Tuesday, August 18th. SVB Leerink started coverage on shares of HL Acquisitions in a research note on Monday, July 27th. They issued an “outperform” rating and a $17.00 price objective on the stock. Zacks Investment Research lowered shares of HL Acquisitions from a “hold” rating to a “sell” rating in a research note on Wednesday, September 23rd. Finally, Jefferies Financial Group started coverage on shares of HL Acquisitions in a research note on Friday, July 24th. They issued a “buy” rating and a $14.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. HL Acquisitions presently has a consensus rating of “Buy” and a consensus price target of $19.00.

The company has a 50 day moving average price of $9.58.

HL Acquisitions (NASDAQ:IMTX) last issued its quarterly earnings results on Thursday, September 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.20). The firm had revenue of $7.70 million for the quarter, compared to analyst estimates of $8.49 million. As a group, sell-side analysts expect that HL Acquisitions Corp. will post -1.28 earnings per share for the current fiscal year.

HL Acquisitions Company Profile (NASDAQ:IMTX)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

See Also: Learning About the VIX – Volatility Index

Receive News & Ratings for HL Acquisitions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HL Acquisitions and related companies with MarketBeat.com's FREE daily email newsletter.